A CAR T therapy produced by J&J and Legend Biotech significantly reduces risk of relapse for multiple myeloma patients who have received one to three previous lines of treatment, according to early study results.
CAR T Therapy Dramatically Reduces Risk Of Relapse For Multiple Myeloma
